MINIMUM bio utilizes a phage display technology platform to rapidly identify protein binding partners for small molecules and biologics, significantly enhancing early-stage drug target discovery. This approach reduces the time and cost of preclinical R&D, enabling the pharmaceutical industry to develop safer and more effective therapeutics efficiently.
Funding
Funding not disclosed
Founders
Product
Problem
The drug discovery process is often slow and expensive, particularly in the early stages of identifying appropriate drug targets. Traditional methods for identifying protein binding partners for small molecules and biologics can be time-consuming and resource-intensive.
Solution
MINIMUM bio offers a phage display technology platform designed to accelerate and streamline early-stage drug target discovery. The platform enables rapid identification of protein binding partners for small molecules and biologics, reducing the time and cost associated with preclinical research and development. By improving the efficiency of target identification, MINIMUM bio aims to facilitate the development of safer and more effective therapeutics. The technology is designed to be both fast and agnostic, allowing for broad applicability across various therapeutic areas.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in drug discovery and development.
Features
- Phage display technology for identifying protein binding partners.
- Rapid screening process to accelerate target discovery.
- Applicable to both small molecules and biologics.
- Aims to reduce preclinical R&D time and costs.